Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study

Fig. 3

Kaplan–Meier curve of the incidence probability for the primary and secondary outcomes. No significant difference was observed in the incidence probability of the primary outcome between new dapagliflozin and empagliflozin users among patients with type 2 diabetes A. The primary outcomes included heart failure-related events, myocardial infarction, ischemic stroke, and cardiovascular death. Regarding the secondary outcomes, the risks of heart failure-related events B, ischemic stroke C, myocardial infarction D, and cardiovascular death E were compared

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840